宋文哲 郭 萌 祝志強(qiáng) 路 欣
?
乳腺顆粒細(xì)胞瘤1例報(bào)告及合并文獻(xiàn)分析
宋文哲 郭 萌 祝志強(qiáng) 路 欣
目的 分析乳腺顆粒細(xì)胞瘤的臨床病理特點(diǎn),并指導(dǎo)臨床診治。方法 回顧性分析1例乳腺顆粒細(xì)胞瘤的臨床病理資料。結(jié)果 乳腺顆粒細(xì)胞瘤很少見(jiàn),臨床癥狀不典型,與乳腺癌很難鑒別,細(xì)針穿刺及術(shù)中快速冰凍病理檢查無(wú)法確診。手術(shù)治療后,預(yù)后良好。結(jié)論 乳腺顆粒細(xì)胞瘤的診斷手術(shù)后病理診斷結(jié)果為標(biāo)準(zhǔn),其特征性表現(xiàn)為胞質(zhì)內(nèi)存在嗜酸性顆粒。
乳腺腫瘤/病理學(xué);顆粒細(xì)胞瘤;免疫組織化學(xué)
(ThePracticalJournalofCancer,2017,32:1361~1363)
顆粒細(xì)胞瘤(granular cell tumor,GCT)是1種少見(jiàn)的軟組織腫瘤,多見(jiàn)于舌、口腔和皮下組織。發(fā)生于乳腺的顆粒細(xì)胞瘤少見(jiàn),大多數(shù)為良性,多見(jiàn)于30~50歲的絕經(jīng)前女性。臨床體檢、乳腺影像學(xué)及超聲檢查與乳腺癌極為相似,細(xì)針穿刺及術(shù)中快速冰凍病理檢查無(wú)法確診,往往通過(guò)術(shù)后常規(guī)石蠟病理檢查及免疫組織化學(xué)檢測(cè)才能確診。本文通過(guò)復(fù)習(xí)徐州醫(yī)科大學(xué)附屬醫(yī)院2013年收治的1例乳腺顆粒細(xì)胞瘤的病例資料,并結(jié)合文獻(xiàn)探討GCT的臨床表現(xiàn)、診斷及鑒別診斷、治療和預(yù)后,從而提高對(duì)該病的認(rèn)識(shí)并減少誤診、誤治。
患者,女性,54歲。因右乳發(fā)現(xiàn)無(wú)痛性腫塊2年收入院?;颊?年前體檢時(shí)行乳腺鉬靶檢查發(fā)現(xiàn)右乳占位,提示為良性,無(wú)疼痛、無(wú)發(fā)熱、無(wú)乳頭溢液,當(dāng)時(shí)建議手術(shù)治療,患者拒絕,遂定期復(fù)查,腫塊無(wú)明顯增大。入院前1月再次行鉬靶檢查,提示為惡性病變,建議手術(shù)治療,遂來(lái)我院就診。入院時(shí)體檢:雙乳對(duì)稱下垂,無(wú)乳頭凹陷及溢液,無(wú)橘皮征,右乳內(nèi)上象限1點(diǎn)位距乳頭8 cm處觸及一3 cm×2 cm質(zhì)硬的腫塊,邊界不清,活動(dòng)度差,表面不光滑,右乳及雙側(cè)腋窩未觸及腫大淋巴結(jié)。乳腺彩超檢查:右乳1:00距乳頭約7.5 cm探及低回聲結(jié)節(jié),延伸至淺層及深部脂肪層內(nèi),與胸大肌分界不清,周圍示高回聲暈,大小約2.0 cm×1.3 cm×1.3 cm,界不清,內(nèi)有血流信號(hào),提示癌聲像。鉬靶檢查:右乳內(nèi)上象限深部可見(jiàn)結(jié)節(jié)狀高密度影,大小約1.6 cm×1.7 cm,邊界尚清,密度均勻,部分邊緣可見(jiàn)毛刺樣改變,雙乳未見(jiàn)明顯異常鈣化灶影。BI-RADS:4類,疑似惡性,建議MRI檢查明確與胸大肌關(guān)系。磁共振檢查:右乳內(nèi)上象限示結(jié)節(jié)狀異常信號(hào)影,呈長(zhǎng)T1信號(hào),T2壓脂呈等、高信號(hào),DWI序列呈高信號(hào),病灶邊緣可見(jiàn)分葉及毛刺征,大小約1.4 cm×1.6 cm×1.4 cm,增強(qiáng)檢查病灶呈明顯強(qiáng)化,動(dòng)態(tài)增強(qiáng)曲線趨向于平臺(tái)型。診斷:右乳內(nèi)上象限占位性病變(乳腺癌可能大),建議穿刺活檢。術(shù)中所見(jiàn):腫塊直徑約3 cm×3 cm,侵犯皮下脂肪層,與胸大肌有粘連,質(zhì)地硬,界限不清,剖開腫塊,見(jiàn)切面一結(jié)節(jié),直徑1 cm,切面灰黃,質(zhì)地硬。術(shù)中冰凍病理診斷:(右乳腺)傾向?yàn)轭w粒細(xì)胞瘤。術(shù)后常規(guī)病理結(jié)果:(右乳)顆粒細(xì)胞瘤。免疫組織化學(xué)結(jié)果:S100+;NSE弱+;Calretinin+;inhibin+;CKp、EMA、ER、PR均陰性;Ki67+<1%。隨訪至今,無(wú)異常表現(xiàn)。
顆粒細(xì)胞腫瘤最初由Abrikossoff報(bào)道,可發(fā)生于任何部位、任何年齡[1],多見(jiàn)于30~60歲之間,約半數(shù)發(fā)生于皮膚及皮下組織,近1/3發(fā)生于舌。發(fā)生于乳腺組織的顆粒細(xì)胞瘤很少見(jiàn),約占所有CGT的5%~15%之間,大約每1000例乳腺癌病例中有1例是顆粒細(xì)胞瘤[2]。乳腺GCT多見(jiàn)于女性,男性罕見(jiàn),男女比例約為1∶9[3-4]。 臨床上乳腺GCT通常表現(xiàn)為腺體實(shí)質(zhì)內(nèi)單發(fā)、質(zhì)硬、無(wú)痛性腫塊。部分乳腺GCT還表現(xiàn)出浸潤(rùn)性乳腺癌的一些特性,如位置比較表淺的腫瘤可以侵犯皮膚、皮下脂肪組織,導(dǎo)致皮膚局部皺縮和/或乳頭內(nèi)陷;位于乳腺深部的腫塊可侵犯胸肌筋膜和胸大肌,很難與乳腺癌相鑒別[5]。本例患者術(shù)中見(jiàn)腫塊侵犯脂肪組織,并與胸大肌粘連、浸潤(rùn)。
乳腺GCT鉬靶表現(xiàn)各異,大多數(shù)表現(xiàn)為圓形,邊界清楚、密度不均的腫塊,有的腫塊表現(xiàn)為不規(guī)則,密度不均勻、邊緣呈毛刺狀或星狀,甚至有胸大肌侵犯的表現(xiàn)[6],與乳腺癌鉬靶表現(xiàn)極為相似。值得一提的是乳腺GCT鉬靶通常沒(méi)有鈣化,如果出現(xiàn)鈣化,通常提示為惡性GCT[1]。本例腫塊邊界尚清,密度均勻,部分部分邊緣可見(jiàn)毛刺樣改變,可疑侵犯胸大肌,未見(jiàn)鈣化,BI-RADS:4類。
乳腺GCT的超聲圖像通常表現(xiàn)為實(shí)性,回聲不均勻、邊界不清楚的腫塊[7],有時(shí)在腫塊邊緣可以見(jiàn)到豐富的血管回聲[8]。由于乳腺GCT缺乏特征性的超聲表現(xiàn),且很難與乳腺癌相鑒別,因此乳腺GCT超聲圖像往往提示為惡性[9]。
大多數(shù)乳腺GCT的MRI表現(xiàn)為形態(tài)不規(guī)則、邊緣毛刺狀的腫塊影。在T1加權(quán)像上可見(jiàn)低或中等信號(hào)影;T2加權(quán)像呈極低信號(hào)影或無(wú)信號(hào)影[5,10];增強(qiáng)檢查表現(xiàn)各異,表現(xiàn)為均質(zhì)或不均質(zhì)腫塊影,伴有或不伴有邊緣強(qiáng)化[10];動(dòng)態(tài)增強(qiáng)曲線呈現(xiàn)出平臺(tái)型,與浸潤(rùn)性乳腺癌MRI表現(xiàn)極其相似[11]。
乳腺GCT僅憑術(shù)前細(xì)針穿刺細(xì)胞學(xué)檢查(FNAC)和術(shù)中快速冰凍病理很難確診,只能依靠術(shù)后常規(guī)石蠟病理及免疫組織化學(xué)確診。鏡下GCT細(xì)胞呈圓形或卵圓形,境界清楚,胞體寬大,胞質(zhì)豐富,其特征性表現(xiàn)為胞漿內(nèi)存在嗜酸性顆粒[12]。最初GCT被認(rèn)為是肌源性腫瘤,因而被稱為肌母細(xì)胞瘤。由于細(xì)胞內(nèi)高表達(dá)S-100蛋白和神經(jīng)元特異性烯醇化酶(neuron-specific enolase,NSE),因此目前認(rèn)為顆粒細(xì)胞瘤來(lái)源于神經(jīng)鞘的雪旺細(xì)胞[5,13]。S100是判斷良性乳腺GCT的1個(gè)敏感指標(biāo),但特異性不強(qiáng),因?yàn)?0%的乳腺癌組織中也表達(dá)S100[14]。其他陽(yáng)性指標(biāo)包括CD86,inhibin-α,calretinin,CD57等[5]。本例中S100,Calretinin和inhibin陽(yáng)性,NSE弱陽(yáng)性。需要指出的是:GCT會(huì)出現(xiàn)類似乳腺癌的表現(xiàn),如腫瘤邊界不清,累及鄰近結(jié)構(gòu)及侵犯神經(jīng),但即使出現(xiàn)這種情況,也不表示GCT 為惡性。Fanburg-Smith等[15]提出惡性GCT的6個(gè)指標(biāo):瘤細(xì)胞變梭形,空泡狀核并有大核仁,核分裂象(≥2個(gè)/高倍視野,HPF),腫瘤性壞死,高核質(zhì)比和多形性細(xì)胞核。王堅(jiān)等建議將惡性顆粒細(xì)胞瘤的核分裂象計(jì)數(shù)標(biāo)準(zhǔn)修訂為>5個(gè)/50HPF[16]。滿足3個(gè)或3個(gè)以上指標(biāo)即可診斷為惡性GCT,滿足2個(gè)指標(biāo)診斷為不典型GCT,其中核分裂像最重要[10]。
乳腺GCT通常為良性,局部擴(kuò)大切除即可達(dá)到治愈的目的,不主張行腋窩淋巴結(jié)清掃或前哨淋巴結(jié)活檢,預(yù)后較好,但切除不徹底可出現(xiàn)局部復(fù)發(fā)[1,17]。乳腺惡性GCT罕見(jiàn),手術(shù)治療同其他乳腺惡性腫瘤,預(yù)后較差,化療及放療不能改善惡性GCT的預(yù)后[1,18]。
[1] Qureshi NA,Tahir M,Carmichael AR.Granular cell tumor of the soft tissue:a case report and literature review〔J〕.Int Sem Surg Onc,2006,3 (1) :21.
[2] Adeniran A,Al-Ahmadie H,Mahoney MC,et al.Granular cell tumor of the breast:a series of 17 cases and review of the literature〔J〕.Breast J,2004,10(6):528-531.
[3] Patel HB,Leibman AJ.Granular cell tumor in a male breast:mammographic,sonographic,and pathologic features〔J〕.J Clin Ultrasound,2013,41(2):119-121.
[4] Kim EY,Kang DK,Kim TH,et al.Granular cell tumor of the male breast:two case descriptions and brief review of the literature〔J〕.J Ultrasound Med,2011,30(9):1295-1301.
[5] Brown AC,Audisio RA,Regitnig P.Granular cell tumor of breast〔J〕.Surg Oncol,2011,20(2):97-105.
[6] Leo C,Briest S,Pilch H,et al.Granular cell tumor of the breast mimicking breast cancer〔J〕.Eur J Obstet Gynecol Reprod Biol,2006,127(2):268-270.
[7] Irshad A,Pope TL,Ackerman SJ,et al.Characterization of sonographic and mammographic features of granular cell tumors of the breast and estimation of their incidence〔J〕.J Ultrasound Med,2008,27(3):467-475.
[8] Yang WT,Edeiken-Monroe B,Sneige N,et al.Sonographic and mammographic appearances of granular cell tumors of the breast with pathological correlation〔J〕.J Clin Ultrasound,2006,34(4):153-160.
[9] Iglesias A,Arias M,Santiago P,et al.Benign breast lesions that simulate malignancy:magnetic resonance imaging with radiologic-pathologic correlation〔J〕.Curr Probl Diagn Radiol,2007,36(2):66-82.
[10] Scaranelo AM,Bukhanov K,Crystal P,et al.Granular cell tumor of the breast:MRI findings and review of the literature 〔J〕.Br J Radiol,2007,80(960):970-974.
[11] Maki DD,Horne D,Damore LJ,et al.Magnetic resonance appearance of granular cell tumor of the breast 〔J〕.Clin Imaging,2009,33(5):395-397.
[12] 郭云泉,趙 峰,房新志,等.乳腺顆粒細(xì)胞瘤 9例臨床病理分析〔J〕.臨床與實(shí)驗(yàn)病理學(xué)雜志,2011,27(5):495-498.
[13] Rekhi B,Jambhekar NA.Morphologic spectrum,immunohistochemical analysis,and clinical features of a series of granular cell tumors of soft tissues:a study from a tertiary referral cancer center〔J〕.Ann Diagn Pathol,2010,14(3):162-167.
[14] Montagnese MD,Roshong-Denk S,Zaher A,et al.Granular cell tumor of the breast〔J〕.Am Surg,2004,70(1):52-54.
[15] Fanburg-Smith JC,Meis-Kindblom JM,F(xiàn)ante R,et al.Malignant granular cell tumor of soft tissue:diagnostic criteria and clinicopathologic correlation〔J〕.Am J Surg Pathol,1998,22(7):779-794.
[16] 王 堅(jiān),朱雄增,張仁元.惡性顆粒細(xì)胞瘤10例臨床病理學(xué)觀察及文獻(xiàn)復(fù)習(xí)〔J〕.中華病理學(xué)雜志,2004,33(6):497-502.
[17] Papalas JA,Wylie JD,Dash RC.Recurrence risk and margin status in granular cell tumors of the breast:a clinicopathologic study of 13 patients〔J〕.Arch Pathol Lab Med,2011,135(7):890-895.
[18] Akahane K,Kato K,Ogiso S,et al.Malignant granular cell tumor of the breast:case report and literature review〔J〕.Breast Cacner,2015,22(3):317-323.
(編輯:吳小紅)
Granular Cell Tumor of the Breast:1 Case Report and Review of Literature
SONG Wenzhe,GUO Meng,ZHU Zhiqiang,et al.
Affiliated Hospital of Xuzhou Medical University,Xuzhou,221002
Objective To review the clinical and pathological feathers of granular cell tumor (GCT) of breast.Methods
1 case of granular cell tumor of breast was reported,and the clinical presentations,medical image findings,surgical procedure,pathological examination and follow-up data were analyzed.Results Granular cell tumor of breast was rare,the clinical presentations were atypical,and it was not easy to be distinguished with breast cancer.The diagnosis cannot be confirmed by fine needle aspiration cytology and intraoperative rapid frozen pathological examination.The prognosis was good after operation.Conclusion The diagnosis of granular cell tumor of breast depend on pathological examination,which include routine paraffin section and immunohistochemical examination,and the typical characteristic of GCT is that there are eosinophilic granulars in the cytoplasm.
Breast tumor/pathology;Granular cell tumor;Immunohistochemistry
221002 徐州醫(yī)科大學(xué)附屬醫(yī)院
10.3969/j.issn.1001-5930.2017.08.042
R737.9
D
1001-5930(2017)08-1361-03
2016-08-19
2017-04-10)